Literature DB >> 2918053

Augmentation of growth hormone secretion in children with constitutional growth delay by short term clonidine administration: a pulse amplitude-modulated phenomenon.

S Loche1, R Puggioni, T Fanni, S G Cella, E E Müller, C Pintor.   

Abstract

We evaluated the effect of chronic clonidine administration on 24-h integrated GH secretion (IC-GH) in eight children (six boys and two girls; age, 6.0-13.0 yr) with constitutional growth delay (CGD). Clonidine was given orally in a daily dose of 0.1 mg/m2 at bedtime for 6 months; 24-h secretion studies were performed before and after 2 months of treatment. Clonidine caused a significant augmentation (P less than 0.02) of mean IC-GH from 2.6 +/- 0.4 (+/- SE) to 4.6 +/- 0.6 micrograms/L. The increase in IC-GH was mainly the result of increased GH pulse amplitude, which rose from 12.3 +/- 1.3 to 18.2 +/- 2.1 micrograms/L (P less than 0.01). The mean GH pulse amplitude was significantly higher (P less than 0.02) during sleep (15.9 +/- 2.4 micrograms/L) than during the awake hours (8.4 +/- 1.5 micrograms/L) before treatment. During clonidine treatment the mean GH pulse amplitude during the awake hours (15.0 +/- 3.8 micrograms/L) was similar to that during sleep (20.3 +/- 3.1 micrograms/L). GH pulse frequency was not altered by treatment during either the awake or sleep hours. The mean insulin-like growth factor I levels after 2 (1400 +/- 300 U/L) and 6 (1760 +/- 430 U/L) months of treatment were significantly higher (P less than 0.02 and P less than 0.05, respectively) than the pretreatment value (920 +/- 240 U/L). After 2 months of clonidine treatment, growth velocity increased from 3.1 +/- 0.5 to 10.2 +/- 1.0 cm/yr (P less than 0.001), and after 6 months of treatment is was still significantly higher (7.0 +/- 0.7 cm/yr; P less than 0.02) than that before treatment. These results confirm the ability of clonidine to accelerate growth in children with CGD and indicate that clonidine is capable of increasing IC-GH levels. They also reinforce the view that many children with CGD have decreased endogenous GH secretion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918053     DOI: 10.1210/jcem-68-2-426

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay.

Authors:  S Loche; C Pintor; P Cambiaso; A Lampis; D Carta; R Corda; M Cappa
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

Review 2.  Clonidine treatment in children with short stature.

Authors:  S Loche; A Lampis; S G Cella; V Locatelli; E E Müller; C Pintor
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

Review 3.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

4.  Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine.

Authors:  F Orio; N Padovano; L Cinquanta; A Colao; B Merola; S Longobardi; E Rossi; V Esposito; F Orio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.